ACADIA PHARMACEUTICALS INC
ACADUnited States
92 filed reports · 487 financial concepts · 2 earnings calls
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $1.07BFY2025 · to Dec 31, 2025+11.9% from $958M10-K | $342MQ3 FY2026 · to Sep 30, 2026+22.8% from $279M10-Q |
| Net income | $391MFY2025 · to Dec 31, 2025+72.7% from $226M10-K | $53.5MQ3 FY2026 · to Sep 30, 2026−25.4% from $71.8M10-Q |
| Operating income | $105MFY2025 · to Dec 31, 2025−54.6% from $231M10-K | $71.7MQ3 FY2026 · to Sep 30, 2026+101% from $35.8M10-Q |
Filed reports
92 reports · Jun 2011 to Sep 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 63 guidance figures, 58 earnings-release figures, 28 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 47 | 5,243 | Jun 2011 to Sep 2026 |
| Current · 8-KSEC EDGAR | 30 | 88 | Dec 2012 to Sep 2026 |
| Annual · 10-KSEC EDGAR | 15 | 5,142 | Dec 2011 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 10-Q | Sep 30, 2026 | Nov 5, 2026 | 343 | Open |
| FY2026 Q3 | 8-K | Sep 30, 2026 | Nov 4, 2026 | 25 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 211 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 216 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 777 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 2 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 13, 2026 | 1 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 153 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 152 | Open |
Financial data
487 concepts · 10,473 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial467 concepts · 10,215 facts · Dec 2009 to Sep 2026
- Cash and cash equivalents at carrying value84 · Dec 2009 to Sep 2026
- Net income loss84 · Dec 2009 to Sep 2026
- Operating income loss84 · Dec 2009 to Sep 2026
- Research and development expense84 · Dec 2009 to Sep 2026
- Revenue84 · Dec 2009 to Sep 2026
- Depreciation82 · Dec 2009 to Sep 2026
- Increase decrease in accounts payable82 · Dec 2009 to Sep 2026
- Increase decrease in accrued liabilities82 · Dec 2009 to Sep 2026
- Proceeds from issuance of common stock82 · Dec 2009 to Sep 2026
- Stockholders equity (US GAAP)81 · Dec 2009 to Sep 2026
- Share based compensation80 · Dec 2009 to Sep 2026
- Accounts payable current79 · Dec 2010 to Sep 2026
- Accretion amortization of discounts and premiums investments79 · Dec 2010 to Sep 2026
- Accrued liabilities current79 · Dec 2010 to Sep 2026
- Antidilutive securities excluded from computation of earnings per share amount79 · Dec 2010 to Sep 2026
- Assets79 · Dec 2010 to Sep 2026
- Assets current79 · Dec 2010 to Sep 2026
- Common stock par or stated value per share79 · Dec 2010 to Sep 2026
- Common stock shares authorized79 · Dec 2010 to Sep 2026
- Common stock shares issued79 · Dec 2010 to Sep 2026
- Common stock shares outstanding79 · Dec 2010 to Sep 2026
- Common stock value79 · Dec 2010 to Sep 2026
- Comprehensive income net of tax79 · Dec 2010 to Sep 2026
- Liabilities and stockholders equity79 · Dec 2010 to Sep 2026
Segment10 concepts · 160 facts · Dec 2022 to Sep 2026
- Revenue42 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)15 · Dec 2022 to Sep 2026
- Royalty expense15 · Dec 2022 to Sep 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Interest income expense nonoperating net14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Other nonoperating income expense14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Gain loss on sale of other assets4 · Dec 2022 to Dec 2025
Guidance2 concepts · 65 facts · Mar 2013 to Nov 2026
- Revenue Guidance61 · Aug 2017 to Nov 2026
- Free Cash Flow Guidance4 · Mar 2013 to May 2013
KPI6 concepts · 22 facts · Sep 2025 to Sep 2026
- Cost of product sales4 · Sep 2025 to Sep 2026
- Product sales, net4 · Sep 2025 to Sep 2026
- Research and development4 · Sep 2025 to Sep 2026
- Selling, general and administrative4 · Sep 2025 to Sep 2026
- Total revenues4 · Sep 2025 to Sep 2026
- Cash, cash equivalents and investment securities2 · Dec 2025 to Sep 2026
Product2 concepts · 11 facts · Dec 2016 to Sep 2026
- Revenue8 · Dec 2016 to Sep 2026
- Cost of goods and services sold (US GAAP)3 · Dec 2016 to Dec 2018
Segments
171 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 160 facts
- Reportable Segment Aggregation Before Other Operating160 · Dec 2022 to Sep 2026
Product or service4 members · 11 facts
- Product6 · Dec 2016 to Dec 2018
- Daybue2 · Sep 2025 to Sep 2026
- Nuplazid2 · Sep 2025 to Sep 2026
- Product And Service Other1 · Dec 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary10 claims from 1 report · Sep 2026
- Management discussion (MD&A) commentary18 claims from 1 report · Sep 2026
- Risk-factor changes229 claims from 13 reports · Dec 2012 to Dec 2024
- Risk factors676 risks from 14 annual reports · 2011 to 2024
Earnings calls
2 calls · Aug 2026 to Nov 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q3Nov 4, 2026
- FY2026 Q2Aug 4, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of ACADIA PHARMACEUTICALS INC (ACAD) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 11, 2026) and refreshed every few hours.